<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20065">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980511</url>
  </required_header>
  <id_info>
    <org_study_id>NeuroVISION v1.0</org_study_id>
    <nct_id>NCT01980511</nct_id>
  </id_info>
  <brief_title>Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN</brief_title>
  <acronym>NeuroVISION</acronym>
  <official_title>Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NeuroVISION Study will characterize the incidence, impact, and risk factors of covert
      stroke in adults undergoing noncardiac surgery. We will determine the incidence of acute
      covert stroke using an MRI study of the brain in the days following noncardiac surgery. We
      will characterize the epidemiology and the impact of covert stroke in patients undergoing
      noncardiac surgery, and its association with cerebral deoxygenation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Postoperative cognitive dysfunction</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive dysfunction, as measured by a decrease of on the Montreal Cognitive Assessment (MoCA) scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring the incidence of acute postoperative covert stroke</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will detect postoperative covert strokes using a MRI study of the brain that will be performed between postoperative days 3 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring cerebral oxygenation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring postoperative delirium</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Delirium will be measured using the Cognitive Assessment Method (CAM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring physical function after surgery</measure>
    <time_frame>30 days and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physical function will be measured using two instruments; the Modified Rankin Scale and the Lawton Instrumental Activities of Daily Living (iADL) Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring quality of life after surgery</measure>
    <time_frame>30 days and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use the EQ-5D questionnaire to assess the patients' health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring depressive symptoms after surgery</measure>
    <time_frame>30 days and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use the 5-question version of the Geriatric Depression Scale (GDS-5) to depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring clinical outcomes</measure>
    <time_frame>30 days and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical outcomes: acute cerebral ischemia, covert stroke, overt stroke, transient ischemic attack, delirium, death, myocardial infarction (MI), myocardial injury after noncardiac surgery (MINS), nonfatal cardiac arrest, major adverse cardiovascular events (composite), cardiac revascularization procedures, bleeding, new atrial fibrillation, hypotension, congestive heart failure, new acute renal failure, infection, and dementia and mild cognitive impairment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covert Postoperative Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing elective non-cardiac surgery, ≥ 65 years old and an anticipated
        hospital stay of at least 3 days after elective noncardiac surgery that occurs under
        general or neuraxial anesthesia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥65 years old

          -  An anticipated hospital stay of at least 3 days after elective noncardiac surgery
             that occurs under general or neuraxial anesthesia

          -  Written informed consent for potential participation prior to noncardiac surgery

        Exclusion Criteria:

          -  Contraindication to MRI (e.g. implanted devices not safe for MRI studies,
             claustrophobia, unable to lie flat or still),

          -  Unable or unwilling to attend the follow-up appointments,

          -  Documented history of dementia

          -  Residing in a nursing home,

          -  Undergoing carotid artery surgery or intracranial surgery

          -  Unable to complete neurocognitive testing due to language, vision or hearing
             impairment,

          -  Unable to communicate with the research staff due to language barriers,

          -  Previously enrolled in the NeuroVISION Study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P.J. Devereaux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marko Mrkobrada, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marko Mrkobrada, MD, FRCPC</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40654</phone_ext>
    <email>mmrkobr@uwo.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Dunlop, BSc</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40675</phone_ext>
    <email>valerie.dunlop@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dave Cowan, MD</last_name>
      <phone>905-573-4818</phone>
      <email>cowand@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Krysten Gregus</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>67177</phone_ext>
      <email>gregus@hhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>SAR</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Chan, MD</last_name>
      <phone>852 2632 2736</phone>
      <email>mtvchan@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Tsang</last_name>
      <phone>852 26321905</phone>
      <email>matthew_tsang@cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Campbell, MD</last_name>
      <phone>+64 9 367 0000</phone>
      <email>dcampbell@adhb.govt.nz</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Waymouth</last_name>
      <phone>+64 2 142 7167</phone>
      <email>ewaymouth@adhb.govt.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
